Effect of helicobacter pylori eradication regimen versus standard treatment on gastro-esophageal reflux symptoms in patients with antral gastritis
Phase 3
- Conditions
- Gastroesophageal reflux.Gastro-oesophageal reflux disease without oesophagitis
- Registration Number
- IRCT201202229014N2
- Lead Sponsor
- Vic-chancellor of Research and Technology, Hamadan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- All
- Target Recruitment
- 162
Inclusion Criteria
The patient's with one of the following symptoms: gastro-esophageal reflux, dysphagia; heartburn; nausea; chest pain; and nuisance conditions that lead to awakening the patient will be included if they have endoscopic detection of gastritis and H. pylori infection in biopsy of gastric mucosa.
The patents with following characteristics will be excluded from the study: simultaneous gastritis of fundus and antrum (pangastritis); gastric ulcer; duodenal ulcer; surgical history of esophagus, stomach, or duodenum; and history of using NSAIDs.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency and severity of reflux. Timepoint: After four weeks. Method of measurement: History taking of heartburn, regurgitation, nausea, dysphagia, chest pain, and nocturnal.
- Secondary Outcome Measures
Name Time Method Abdominal pain and diarrhea. Timepoint: Two weeks later. Method of measurement: History taking.